Outcome of Board Meeting held on 21st April 2026 as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Kabra Drugs Ltd's board met on 21st April 2026 and approved several major changes. It appointed Ms. Monam Kapoor (DIN: 09278005) as an Additional Non-Executive Independent Director for a 5-year term; she already serves on the boards of 5 other listed companies. The board also approved a sweeping diversification of business by amending the Main Objects clause of its Memorandum of Association to add new areas including drones and defence equipment, artificial intelligence and software, hospitals and medical equipment, hospitality, dairy products, agro farms, steel products, renewable energy projects, and electric vehicle systems. A Postal Ballot has been initiated seeking shareholder approval for these MOA changes and a proposed change in the company's name. E-voting will run from 9th May 2026 to 8th June 2026, and the Register of Members will be closed during this period.
This is a significant transformation for a small pharmaceutical company moving into defence, AI, healthcare, and renewable energy sectors, which could attract speculative interest but also raises questions about execution capability. Shareholders will need to vote on both the name change and the expanded business scope, making the postal ballot a key event to watch. Diversification of this scale from a drugs company carries both opportunity and execution risk.